

This is the peer reviewed version of the following article:

Synthesis, Characterization, and Selective Delivery of DARPIn-Gold Nanoparticle Conjugates to Cancer Cells / Deyev, Sergey; Proshkina, Galina; Ryabova, Anastasiya; Tavanti, Francesco; Menziani, Maria Cristina; Eidelstein, Gennady; Avishai, Gavriel; Kotlyar, Alexander. - In: BIOCONJUGATE CHEMISTRY. - ISSN 1043-1802. - 28:10(2017), pp. 2569-2574-2574. [10.1021/acs.bioconjchem.7b00410]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

04/05/2026 07:37

(Article begins on next page)

## Synthesis, Characterization and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells

Sergey Deyev, Galina Proshkina, Anastasiya Ryabova, Francesco Tavanti, Maria Cristina Menziani, Gennady Eidelstein, Gabriel Avishai, and Alexander B. Kotlyar

*Bioconjugate Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.bioconjchem.7b00410 • Publication Date (Web): 14 Aug 2017

Downloaded from <http://pubs.acs.org> on August 15, 2017

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



# Synthesis, Characterization and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells

*Sergey Deyev<sup>† ‡\*</sup>, Galina Proshkina<sup>†</sup>, Anastasiya Ryabova<sup>§</sup>, Francesco Tavanti<sup>⊥</sup>, Maria Cristina Menziani<sup>⊥</sup>, Gennady Eidelshtein<sup>#</sup>, Gabriel Avishai<sup>#</sup>, Alexander Kotlyar<sup>#\*</sup>*

<sup>†</sup>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya St, 16/10, Moscow 117997, Russia

<sup>‡</sup>National Research Tomsk Polytechnic University, 30 av. Lenina, Tomsk, 634050 Russia

<sup>§</sup>Prokhorov General Physics Institute, Russian Academy of Sciences, 38 Vavilova St, Moscow 119991, Russia

<sup>⊥</sup>Department of Chemical and Geological Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy

<sup>#</sup>Department of Biochemistry and Molecular Biology, George S. Wise Faculty of Life Sciences and the Center of Nanoscience and Nanotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel

KEYWORDS: DARPin, gold nanoparticles, tumor cells, molecular dynamics simulations.

## ABSTRACT

We demonstrate that the designed ankyrin repeat protein (DARPin) <sub>9-29</sub>, which specifically targets human epidermal growth factor receptor 2 (HER 2), binds tightly to gold nanoparticles (GNPs). Binding of the protein strongly increases the colloidal stability of the particles. The results of experimental analysis and molecular dynamics simulations show that approximately 35 DARPin <sub>9-29</sub> molecules are bound to the surface of a 5 nm GNP and that the binding does not involve the receptor-binding domain of the protein. The confocal fluorescent

1  
2  
3 microscopy studies show that the DARPin-coated GNP conjugate specifically interacts with  
4  
5 the surface of human cancer cells overexpressing epidermal growth factor receptor 2 (HER2)  
6  
7 and enters the cells by endocytosis. The high stability under physiological conditions and  
8  
9 high affinity to the receptors overexpressed by cancer cells make conjugates of plasmonic  
10  
11 gold nanostructures with DARPin molecules promising candidates for cancer therapy.  
12

## 13 INTRODUCTION


14  
15 Cancer is one of the deadliest diseases. Efforts of many research laboratories worldwide are  
16  
17 focused on specific targeting and elimination of cancer cells and tumors. At present, radiation  
18  
19 and chemotherapy together with surgery are the most widely used treatment strategies  
20  
21 employed to control and prevent different types of cancer. Despite a considerable success  
22  
23 achieved in cancer prevention there is a great need for new methods and technologies that can  
24  
25 ensure efficient and specific eradication of cancer cells without damaging healthy ones.  
26  
27 Photothermal therapy (PTT) using nanoparticles is a promising approach for selective  
28  
29 elimination of cancer cells<sup>1-4</sup>. Spherical gold particles strongly absorb light in the visible  
30  
31 range and are capable to convert the energy of the absorbed light into heat. The amount of  
32  
33 heat released by GNPs upon illumination<sup>5</sup> is sufficient to kill cancer cells in the vicinity of the  
34  
35 nanoparticle. In order to be useful for PTT, the particles should be specifically delivered to  
36  
37 pathological cells. One way to address this challenge is to functionalize the nanoparticles with  
38  
39 tumor-specific targeting ligands that can be recognized by receptors overexpressed in cancer  
40  
41 cells. Different proteins, such as growth factors, transferrin, and antibodies, were employed to  
42  
43 specifically deliver nano-sized objects to pathological cells and tissues.<sup>6-10</sup> Binding of  
44  
45 antibodies to nanoparticles in many cases leads to strong reduction of their specific affinity to  
46  
47 antigens. This is mainly due to multiple orientations of antibody molecules on the surface of  
48  
49 the nanoparticle and to distortion of the antibody's structure caused by interaction with the  
50  
51 metal.<sup>11, 12</sup> Designed ankyrin repeat proteins (DARPins), a novel class of non-IgG scaffolds  
52  
53 based on naturally occurring ankyrin repeats,<sup>13</sup> circumvent the problems of complexity and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 instability and thus seem to be ideal ligands for targeting GNPs and other nano-objects to  
4 tumor-specific receptors. DARPins are small (13–20 kD), highly soluble in water, stable at  
5 different experimental conditions and characterized by very high affinity to their protein  
6 targets<sup>13-16</sup>. A set of DARPins that specifically bind to human epidermal growth factor  
7 receptor 2 (HER2) overexpressed in breast cancer and ovarian cells have been reported<sup>14, 17</sup>.  
8  
9 It has been demonstrated recently<sup>18-20</sup> that conjugates between DARPins and toxic proteins  
10 can specifically bind to cells through interaction with the membrane-associated receptors and  
11 cause cell death. To the best of our knowledge, no data are available on interaction of noble  
12 metal nanoparticles with DARPins and on targeted delivery of the DARPIn-nanoparticle  
13 conjugates to cancer cells.  
14  
15

16 Here we show that approximately 35 DARPIn\_9-29 molecules bind tightly to 5 nm GNPs.  
17 The protein coating layer protects the particles from aggregation; the DARPIn-nanoparticle  
18 conjugates (DARPIn-GNPs) are stable at high (up to 0.5 M) salt concentrations, in contrast to  
19 commonly used citrate-protected GNPs that completely and rapidly precipitate out of the  
20 solution at salt concentrations higher than 20 mM. DARPIn-GNPs specifically bind to SK-  
21 BR-3 cells that overexpress receptor HER2 and are efficiently internalized into them by  
22 endocytosis.  
23  
24

## 25 RESULTS AND DISCUSSION


26 We have demonstrated that incubation of 5 nm (in diameter) GNPs with DARPIn\_9-29 yields  
27 stable DARPIn-GNP conjugates that do not aggregate at relatively high (up to 0.5M) salt  
28 concentrations in contrast to the parent citrate-protected GNPs that precipitate out of the  
29 solution at salt concentrations higher than 20 mM. This is consistent with the formation of a  
30 protective protein layer on the surface of a nanoparticle<sup>21-23</sup>. The formation of the layer is  
31 supported by the AFM imaging analysis of the nanoparticles. As seen in Figure 1, the average  
32 diameter (corresponding to the height measured by AFM) of the DARPIn-coated particles is  
33 greater by ~4 nm than that of the bare (non-coated) GNPs (see Figure 1).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1.** AFM images (A, B) and statistical height analysis (C, D) of more than 1000 GNPs (A, C) and DARPin-GNPs (B, D). The samples were deposited on a mica surface and imaged as described in Experimental Procedures. The average height (corresponding to diameter of GNPs) of DARPin-coated and bare GNPs are equal to  $9.2 \pm 1.8$  and  $4.9 \pm 0.9$  nm respectively ( $n \geq 1000$ ).

The number of DARPin molecules bound to a particle was estimated spectrophotometrically using an extinction coefficient of  $4.6 \times 10^3 \text{ M}^{-1}\text{cm}^{-1}$  at 280 nm and  $10^7 \text{ M}^{-1}\text{cm}^{-1}$  at 520 nm for the DARPin and 5 nm (in diameter) GNPs, respectively. Contribution of the nanoparticle to the absorption of the conjugate at 280 nm is very high, making it impossible to determine the protein concentration. To quantify the protein content we have treated the conjugate with potassium cyanide. The treatment completely bleaches the absorption of the nanoparticles leaving the spectrum of the DARPin almost unaffected. The results of the spectral analysis (see Experimental Procedures for details) show that the DARPin to the GNP stoichiometry in the conjugate is approximately equal to 35.


Coarse-grained molecular dynamics (MD) simulations, carried out to study the interactions of DARPin proteins with GNPs at the molecular level, corroborate these results. Figure 2 shows the process of the protein corona formation during the simulation run. Fast protein adsorption



**Figure 2.** Time evolution of the number of protein bound to the 5 nm GNP, and snapshots of the DARPin corona around GNP taken at 50 ns and 200 ns. Each protein is represented by different colour.

can be observed during the first 50 ns, then, the rate of adsorption slows down as the GNP surface becomes crowded. Finally a plateau corresponding to approximately 35 adsorbed protein molecules is obtained after 200 ns of simulation. The calculated diameter of the coated GNP is  $\sim 9 \pm 1$  nm. This result fits nicely with the diameter estimation by AFM (see Figure 1).


As seen in Figure 3 the DARPin molecules interact with the GNP through several domains, represented by the yellow spheres. Fortunately, the HER2 receptor-binding domain of the



**Figure 3.** Cartoon representation of DARPin\_9-29 (top) docked to the HER2 (bottom). The DARPin molecule helices, sheets and coils are shown in blue, yellow and green respectively. The contact region between DARPin and HER2 is highlighted in red. Yellow spheres represent the DARPin regions, which are most probably involved in anchoring the protein to the GNP. The structure of the DARPin-HER2 complex<sup>14</sup> was retrieved from the RCSB PDB<sup>28</sup> (PDB ID: 4HRL).


DARPin is not involved in binding to the nanoparticle (see Figure 3). We thus expected that the binding affinity of the DARPin to HER2 will not be affected by interaction with the nanoparticle. The effect of the conjugates on adenocarcinoma cells (SK-BR-3) overexpressing HER2 demonstrated that this is indeed the case. Binding of the conjugate and its internalization into the cells was studied using fluorescent confocal microscopy. The DARPin-coated particles lacking fluorescence in the visible range of the absorption spectrum, were first labelled with FITC (DARPin-FITC-GNPs) as described in Experimental Procedures.

We have also used conjugates of the nanoparticles with the highly fluorescent hybrid protein, DARPIn-m-Cherry (DARPIn-m-Cherry-GNPs). We have shown that treatment of SK-BR-3 cells with either of the above conjugates at 4°C results in staining of the cell membranes (Figure 4, A and B); no fluorescence was detected either in the cytoplasm or in the nuclei. The staining is specific with respect to SK-BR-3 cells; CHO cells, lacking HER2 receptors show no fluorescence when treated under identical conditions (Figure 4, C and D). Treatment of



**Figure 4.** Specific interaction of DARPIn-FITC-GNPs and DARPIn-mCherry-GNPs with HER2 receptors on cell surface. SKBR-3 (A, B) and CHO (C, D) cells were incubated with DARPIn-FITC-GNPs (A, C) or DARPIn-mCherry-GNPs (B, D) at 4°C, as described in Experimental Procedures. Confocal fluorescent images of the cells were acquired at excitation wavelengths of 488 (A, C) or 561 nm (B, D). Superimposed images of the cells in blue-green and blue-red fluorescence channels are presented in panels A, C and B, D respectively. Nuclei were stained with Hoechst 33342.

SK-BR-3 cells with DARPin-FITC-GNP and DARPin-m-Cherry-GNP conjugates at 37°C leads to the appearance (in tens of minutes) of bright green and red fluorescent spots in the cytoplasm, respectively (see Figure 5, A and B). The kinetics of the internalization process




**Figure 5.** Specific internalization of DARPin-FITC-GNPs and DARPin-mCherry-GNPs by SKBR-3 cells at 37°C. The cells were treated with DARPin-FITC-GNPs (A) or DARPin-mCherry-GNPs (B) at 37°C as described in Experimental Procedures. Confocal fluorescent images of the cells were acquired at excitation wavelengths of 488 (A) or 561 nm (B). The picture presents superimposed images of the cells in blue-green (A) and blue-red (B) channels. Nuclei were stained with Hoechst 33342.

was studied by monitoring the time course of DARPin-FITC-GNPs appearance in different cell compartments. This was done by co-staining the conjugate with endosomal and lysosomal markers (see Figure 6). Yellow/orange spots in the images correspond to the conjugate located in either endosomes (Figure 6, A and D) or lysosomes (Figure 6, B and E). As evident from the data presented in Figure 6 the conjugate appears in early endosomes 10 min after beginning of the incubation. Accumulation of the conjugate in lysosomes takes about an hour. These results are consistent with internalization of the conjugate into the cell by receptor-mediated (energy-dependent) endocytosis mechanism.

## CONCLUSIONS

We have demonstrated that incubation of citrate-protected GNPs with DARPin<sub>9-29</sub> yields very stable particles that resist high (up to 0.5 M) salt concentrations and do not aggregate



**Figure 6.** Internalization of DARPin-FITC-GNPs by SKBR-3 cells. The cells were incubated with 0.1  $\mu\text{M}$  DARPin-FITC-GNPs. The unbound conjugates were washed away and the cells were subsequently incubated for 10 min (A), 1 h (B), or 2 h (C) at 37°C (see Experimental Procedures). The cells were further treated with Hoechst33342 and LysoTracker to stain the nucleus or lysosomes respectively. For early endosomes staining (A) the cells were treated with BacMan 2.0 a day before the experiment. Fluorescence intensity profiles along white arrows in A, B and C are shown on panels D, E and F, respectively. Green curves in D, E and F correspond to the fluorescence intensity profiles of DARPin-FITC-GNPs and red curves to the fluorescence intensity profiles of the organelle dyes.

under physiological conditions. The experimental results and the results of MD simulations (Figure 2) show that as many as 35 DARPin<sub>9-29</sub> molecules are connected to the nanoparticle. The diameter of the nanoparticle increases from 5 to 9 nm upon coating with the DARPin as evident the AFM analysis (Figure 1) and MD simulations (Figure 2). The thick protein layer surrounding the nanoparticle is responsible for high colloidal stability of the conjugate at high salt concentrations.

1  
2  
3 In many cases binding to nanoparticles leads to a significant reduction of affinity of tumor-  
4 targeting proteins, such as monoclonal antibodies or their fragments, to the receptors.<sup>[11,12]</sup>  
5  
6 We have shown that this is not the case for DARPin\_9-29. The results of calculations showed  
7  
8 that the HER2-binding domain of the protein is not involved in binding to the nanoparticle  
9  
10 (see Figure 2). The DARPin-GNP conjugate strongly and specifically binds to the surface of  
11  
12 HER2-positive cells (Figure 4, A and B) and rapidly (in minutes) enters them by endocytosis  
13  
14 (Figure 5). The high stability under physiological conditions and high affinity to the receptors  
15  
16 overexpressed by cancer cells make conjugates of plasmonic gold nanostructures with  
17  
18 DARPin molecules promising candidates for cancer therapy.  
19  
20  
21

## 22 EXPERIMENTAL PROCEDURES

23  
24 Unless otherwise stated reagents and chemicals were obtained from Sigma-Aldrich (USA)  
25  
26 and were used without further purification.  
27  
28

29 **Synthesis of GNPs.** The citrate-protected 5 nm spherical gold nanoparticles were prepared by  
30  
31 HAuCl<sub>4</sub> reduction with BH<sub>4</sub> essentially as described in.<sup>[24]</sup> The diameter of the nanoparticles  
32  
33 estimated by TEM analysis was equal to 5.05±1 nm. Concentration of the particles was  
34  
35 calculated using an extinction coefficient of  $\sim 1 \times 10^7 \text{ M}^{-1} \text{ cm}^{-1}$  at 520 nm.<sup>[25, 26]</sup>  
36  
37

38 **Preparation of DARPin and DARPin-m-Cherry.** E. coli BL21(DE3) strain was  
39  
40 transformed with plasmids pDARPin-9\_29 or pDARPin-9\_29 -mCherry.<sup>[27]</sup> Fresh  
41  
42 transformants (one colony per mL) were inoculated in 50 mL of the medium containing: 1%  
43  
44 yeast extract, 1% triptone, 25 mM Na<sub>2</sub>HPO<sub>4</sub>, 25 mM KH<sub>2</sub>PO<sub>4</sub>, 100 mM NaCl, 2 mM MgCl<sub>2</sub>  
45  
46 and 0.1 g/L ampicillin and grown at 37°C with vigorous aeration. At a midlog phase (OD at  
47  
48 600 nm  $\sim$  0.5) the incubation temperature was lowered to 28°C and isopropyl-  
49  
50 thiogalactopyranoside was added to a final concentration of 1 mM. After induction for 8 h, the  
51  
52 cells were harvested by centrifugation at 6000 g for 10 min at 4°C. The pellet was  
53  
54 resuspended in a lysis buffer (500 mM NaCl, 20 mM Na-Pi, 30 mM imidazole, 0.5 mg/mL  
55  
56 lysozyme, pH 7.5) and sonicated on ice. Cellular debris was removed by centrifugation at  
57  
58  
59  
60

1  
2  
3 15000 g; the supernatant was passed through a 0.22- $\mu\text{m}$  filter and applied to a  $\text{Ni}^{2+}$ -NTA  
4 column (GE Healthcare, USA) equilibrated with 20 mM Na-Pi (pH 7.5), 500 mM NaCl, and  
5 30 mM imidazole. DARPin was eluted by a linear gradient of imidazole (from 30 to 500 mM).  
6  
7  
8  
9  
10 The eluted protein was passed through Sephadex G-25 column (15  $\times$  80 mm) equilibrated  
11 with 10 mM K-Pi (pH 7.5). The yields of purified DARPin-9\_29 and DARPin-9\_29-mCherry  
12 were approximately equal to 60 and 40 mg per liter of the growth medium respectively.  
13  
14

15  
16 **Coating of GNPs with DARPin and DARPin-m-Cherry.** GNPs (2  $\mu\text{M}$ ; absorption  $\sim$ 20 at  
17 520 nm) were incubated with 1 mg/mL of pDARPin-9\_29 or 3 mg/mL DARPin-9\_29-m-  
18 Cherry in 10 mM K-Pi buffer (pH 7.5) for 20 h. The incubation yielded stable nanoparticles  
19 that do not aggregate at relatively high (up to 0.5 M) salt concentrations in contrast to the  
20 parent nanoparticles that precipitate out of the solution at salt concentrations above 20 mM.  
21 The unbound protein was separated from the particles by size-exclusion chromatography on a  
22 Sepharose 4B column (1 $\times$ 16 cm) equilibrated in 10 mM K-Pi (pH 7.5). The conjugate was  
23 eluted in the void volume of the column, while the DARPin was eluted in the total volume.  
24  
25

26  
27 For visualization by confocal microscopy, the DARPin-GNP conjugate lacking visible  
28 fluorescence was labeled with FITC as follows. The conjugate (absorption at 520 nm  $\sim$  10)  
29 was incubated with 100  $\mu\text{M}$  FITC for 40 h in 20 mM K-Pi (pH 7.5). The unbound dye was  
30 separated from the conjugate on a Sephadex G-25 column (15  $\times$  80 mm) equilibrated with 10  
31 mM K-Pi (pH 7.5). The void volume fraction was collected, left at 20 $^{\circ}\text{C}$  for 16 h, and  
32 repeatedly passed through the same column. This procedure ensured a complete removal of  
33 non-bound FITC from the conjugates.  
34  
35

36  
37 **Estimation of DARPin to GNP ratio in the conjugate.** Concentration of the GNPs was  
38 estimated using an extinction coefficient of  $10^7 \text{ M}^{-1}\text{cm}^{-1}$  at 520 nm. Estimation of the protein  
39 content in the conjugate by absorption spectroscopy is challenging since the nanoparticle  
40 contributes very strongly to the absorbance of the conjugate at 280 nm. To make the  
41 estimation possible, we decomposed the GNP core in the conjugate by treatment with cyanide.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Cyanide etching leads to complete bleaching of the conjugate. The  $\text{Au}(\text{CN})_2^-$  complex formed  
4  
5 during the reaction was removed from the sample by extensive dialysis against 10 mM K-Pi  
6  
7 (pH 7.5). Concentration of the protein was estimated using an extinction coefficient of  
8  
9  $4.6 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$  at 280 nm. The protein concentration in the sample exceeded the GNP  
10  
11 concentration  $\sim 35$  times. Similar result was obtained by computational analysis of the  
12  
13 conjugate using MD simulations, as described below.  
14  
15

16  
17 **Molecular Dynamics Simulations.** The structure of the DARPin - HER2 complex<sup>14</sup> was  
18  
19 retrieved from the RCSB PDB<sup>28</sup> (PDB ID: 4HRL). The process of corona formation on the  
20  
21 GNP was simulated by the coarse grained MD protocol previously developed by Tavanti et  
22  
23 al<sup>29,30</sup>. The 5 nm (in diameter) GNP covered with citrates was modeled by 194 beads each  
24  
25 carrying a negative charge (-3) placed uniformly at a distance of 2.5 nm from the neutrally  
26  
27 charged central bead<sup>31</sup>. A repulsive potential described as a hard spherical wall with a radius  
28  
29 of 25Å was assigned to the central bead in order to avoid penetration of the GNP by citrate  
30  
31 and protein residues. The protein was modeled using a coarse-grained model where each  
32  
33 amino acid is replaced by a single bead located on the  $\alpha$ -carbon<sup>32,33</sup>. The Force Field for  
34  
35 protein is described in<sup>29,30</sup>  
36  
37

38  
39 Molecular dynamics simulations were performed using the DL\_POLY\_2.20 package.<sup>34</sup> The  
40  
41 system was first equilibrated at increasing temperatures, from 10 to 310 K with steps of 50 K;  
42  
43 the temperature was controlled by a Berendsen thermostat with a coupling time of 1fs. Then  
44  
45 three independent production runs at 310 K were performed for 500 ns by changing the initial  
46  
47 velocities and using a stochastic thermostat with coupling time of 1fs.  
48  
49

50 **Cell cultures.** Cell lines SKBR-3 (human breast adenocarcinoma, ATCC number HTB-30),  
51  
52 and CHO-K1 (Chinese hamster ovary, ATCC number CCL-61) were cultured in complete  
53  
54 McCoy's 5A medium with 10% (v/v) heat-inactivated fetal calf serum (Thermo Scientific),  
55  
56  
57  
58  
59  
60

1  
2  
3 100 U/mL penicillin/streptomycin (Paneco) and 2 mM L-glutamine in a humidified incubator  
4  
5 with 5% CO<sub>2</sub> at 37°C.  
6

7 **Confocal microscopy.** SKBR-3 and CHO cells were cultured on glass bottom dishes  
8  
9 (WillCo Well) overnight in 5% CO<sub>2</sub> at 37°C.  
10

11 Binding of DARPIn-FITC-GNPs and the DARPIn-mCherry-GNPs to cell membranes was  
12  
13 studied as follows. The cells were incubated in growth medium containing 0.1 μM of either of  
14  
15 the above conjugates for 10 min at 4°C. The conjugates were washed away with the medium  
16  
17 and the cells were visualized using a laser scanning microscope (Zeiss LSM-710-NLO).  
18  
19

20 Internalization of the conjugates into the cell organelles was conducted as follows. SKBR-3  
21  
22 and CHO cells were incubated in a growth medium containing: 100 nM DARPIn-FITC-GNPs  
23  
24 for 7 min at 37°C. The cells were washed twice with the medium and incubated in the fresh  
25  
26 one for 1, 2 and 3 h at 37°C. For early endosome visualization, the cells were transduced with  
27  
28 Cell Light Early Endosomes-RFP, BacMam 2.0 (Thermo Fisher, USA) in accordance with the  
29  
30 manufacturer's instructions. For visualization of lysosomes, the cells were incubated with 50  
31  
32 nM LysoTrackerRed (Invitrogen) for 20 min at 37°C. The nuclei were stained with 2 nM  
33  
34 Hoechst 33342 for 10 min at 37°C. The cells were finally washed twice with the medium and  
35  
36 visualized using a laser scanning microscope (Zeiss LSM-710-NLO, Germany). DARPIn-  
37  
38 FITC-GNP conjugates were excited at 488 nm; the emission was recorded at 497–562 nm.  
39  
40 LysoTrackerRed, Cell Light Early Endosomes-RFP and DARPIn-mCherry-GNPs were  
41  
42 excited at 561 nm; the emission was recorded at 566–683 nm. Hoechst was excited at 700 nm  
43  
44 using femtosecond laser and the emission was detected at 400–600 nm. The 63× oil Plan-  
45  
46 Apochromat objective with numerical aperture of 1.4 was used in order to obtain high-quality  
47  
48 images.  
49  
50  
51  
52

53 **Atomic Force Microscopy.** AFM was performed on molecules adsorbed on muscovite mica.  
54  
55 100 μL of GNPs and DARPIn-GNPs (absorbance ~0.01 at 520 nm) in 1 mM Mg-acetate were  
56  
57 deposited on a freshly cleaved 1×1 cm mica plate; 5 min later the surface was rinsed with  
58  
59  
60

1  
2  
3 ultra-pure distilled water and dried by blowing nitrogen gas. AFM imaging was performed on  
4  
5 a Solver PRO AFM system (NT-MDT, Russia), in a semi-contact (tapping) mode, using Si-  
6  
7 gold-coated cantilevers (NT-MDT, Russia) with resonance frequency of 80–110 kHz. The  
8  
9 images were “flattened” (each line of the image was fitted to a second-order polynomial, and  
10  
11 the polynomial was then subtracted from the image line) by the Nova image processing  
12  
13 software (NT-MDT, Russia). The images were analyzed and visualized using imaging  
14  
15 software WSXM (Nanotec Electronica S.L., Madrid, Spain)<sup>35</sup>.  
16  
17

#### 18 ACKNOWLEDGEMENTS

19  
20 This work was supported by the Israel Science Foundation, no. 1589/14, by the Russian  
21  
22 Science Foundation (project no.14-24-00106), and by the Far2015 Unimore project.  
23  
24

#### 25 AUTHOR INFORMATION

##### 26 27 **Corresponding Authors**

28  
29 \*E-mail: s2shak@post.tau.ac.il

30  
31 \*E-mail: biomem@mail.ru  
32  
33

#### 34 ORCID

35  
36 Alexander Kotlyar: 0000-0003-0713-6499  
37  
38

#### 39 **Author Contributions**

40  
41 All authors contributed equally to this work.  
42

#### 43 **Funding resources**

44  
45 The Israel Science Foundation and the Russian Science Foundation and the Italian Ministry of  
46  
47 Education and Research.  
48

#### 49 **Notes**

50  
51 The authors declare no competing financial interest.  
52

#### 53 ABBREVIATIONS

54  
55  
56 DARPins, designed ankyrin repeat proteins; HER 2, human epidermal growth factor receptor  
57  
58 2; GNPs, gold nanoparticles; PTT, photothermal therapy; SK-BR-3, human breast  
59  
60

1  
2  
3 adenocarcinoma cells; CHO, chinese hamster ovary cells; MD, molecular dynamics; AFM,  
4  
5 atomic force microscopy; FITC, fluorescein isothiocyanate.  
6

7 REFERENCES

- 8  
9  
10 1. Huang, H., Jain, P. K., El-Sayed, I. H. a,nd El-Sayed, M. A. (2008) Plasmonic  
11  
12 Photothermal Therapy (PPTT) Using Gold Nanoparticles. *Lasers Med. Sci.* 23, 217–228.  
13  
14 2. Huang, X., and El-Sayed, M .A. (2010) Gold Nanoparticles: Optical Properties and  
15  
16 Implementations in Cancer Diagnosis and Photothermal Therapy. *J. Adv. Res.* 1, 13–28.  
17  
18 3. Lucky, S. S., Soo, K. C., and Zhang, Y. (2015) Nanoparticles in Photodynamic Therapy.  
19  
20 *Chem. Rev.*, 115, 1990–2042.  
21  
22 4. Grebenik, E.A., Kostyuk, A.B., and Deyev, S.M. (2016) Upconversion Nanoparticles and  
23  
24 Their Hybrid Assemblies for Biomedical Applications. *Russ. Chem. Rev.* 85, 1277–1296.  
25  
26 5. Govorov, A. O., and Richardson, H. H. (2007) Generating Heat with Metal Nanoparticles.  
27  
28 *Nanotoday* 2, 30-38.  
29  
30 6. Verderio, P., Avvakumova, S., Alessio, G., Bellini, M., Colombo, M., Galbiati, E.,  
31  
32 Mazzucchelli, S., Avila, J. P., Santini, B., and Prosperi, D. (2004) Delivering Colloidal  
33  
34 Nanoparticles to Mammalian Cells: a Nano–Bio Interface Perspective. *Adv. Healthcare*  
35  
36 *Mater.* 3, 957–976.  
37  
38 7. Deyev, S. M., Lebedenko, E. N., Petrovskaya, L. E., Dolgikh, D. A., Gabibov, A. G., and  
39  
40 Kirpichnikov, M. P. (2015) Man-Made Antibodies And Immunoconjugates with Desired  
41  
42 Properties: Function Optimization Using Structural Engineering. *Russ. Chem. Rev.* 84, 1–26.  
43  
44 8. Yan, Y., Such, G. K., Johnston, A. P. R., Best J. P., and Caruso F. (2012) Engineering  
45  
46 Particles for Therapeutic Delivery: Prospects and Challenges. *ACS Nano* 6, 3663–3669.  
47  
48 9. Giljohann, D. A., Seferos, D. S., Daniel, W. L., Massich, M. D., Patel, P. C., and Mirkin, C.  
49  
50 A. (2010) Gold Nanoparticles for Biology And Medicine. *Angew. Chem. Int. Ed.* 49, 3280 –  
51  
52 3294.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 10. Nazareus, M., Zhang, Q., Soliman, M. G., del Pino, P., Pelaz, B., Carregal-Romero, S.,  
4  
5 Rejman, J., Rothen-Rutishauser, B., Clift, M. J. D., Zellner, R., et. al. (2014) *in vitro*  
6  
7 Interaction of Nanoparticles with Mammalian Cells: What Have we Learned Thus Far?  
8  
9 *Beilstein J. Nanotechnol.* 5, 1477–1490.
- 10  
11 11. Avvakumova, S., Colombo, M., Tortora, P., and Prosperi, D. (2014) Biotechnological  
12  
13 Approaches Toward Nanoparticle Biofunctionalization. *Trends Biotechnol.* 32, 11-20.
- 14  
15 12. Occhipinti, E., Verderio, P., Natalello, A., Galbiati, E., Colombo, M., Mazzucchelli, S.;  
16  
17 Salvade, A., Tortora, P., Dogliaa, S. M., and Prosperi, D. (2011) Investigating the Structural  
18  
19 Biofunctionality of Antibodies Conjugated to Magnetic Nanoparticles. *Nanoscale* 3, 387–390.
- 20  
21 13. Binz, H. K., Amstutz, P., Kohl, A., Stumpp, M. T., Briand, C., Forrer, P., Grütter, M. G.,  
22  
23 and Plückthun A. (2004) High-Affinity Binders Selected from Designed Ankyrin Repeat  
24  
25 Protein Libraries. *Nat. Biotechnol.* 22, 575–582.
- 26  
27 14. Jost, C., Schilling, J., Tamaskovic, R., Schwill, M., Honegger, A., and Plückthun, A.  
28  
29 (2013) Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells  
30  
31 Via Binding to the Extracellular Domain of HER2. *Structure* 21, 1979–1991.
- 32  
33 15. Tamaskovic, R., Simon, M., Stefan, N., Schwill, M., and Plückthun, A. (2012) Designed  
34  
35 Ankyrin Repeat Proteins (Darpins): from Research to Therapy. *Meth. Enzymol.* 503, 101–134.
- 36  
37 16. Verdurmen, W. P. R., Luginbühl, M., Honegger, A., and Plückthun, A. (2015) Efficient  
38  
39 Cell-Specific Uptake of Binding Proteins into the Cytoplasm Through Engineered Modular  
40  
41 Transport Systems. *J. Control. Release* 200, 13–22.
- 42  
43 17. Steiner, D., Forrer, P., and Plückthun, A. (2008) Efficient Selection of Darpins with Sub-  
44  
45 Nanomolar Affinities Using SRP Phage Display. *J. Mol. Biol.* 382, 1211–1227.
- 46  
47 18. Martin-Killias, P., Stefan, N., Rothschild, S., Plückthun A., and Zangemeister-Wittke, U.  
48  
49 (2011) A Novel Fusion Toxin Derived from an Epcam-Specific Designed Ankyrin Repeat  
50  
51 Protein Has Potent Antitumor Activity. *Clin. Cancer Res.* 17, 100–110.
- 52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 19. Proshkina, G., Shilova, O., Ryabova, A., Stremovskiy, O., and Deyev S. (2015) A New  
4 Anticancer Toxin Based on HER2/Neu-Specific Darpin and Photoactive Flavoprotein  
5 Minisog. *Biochimie* 118, 116–122.  
6  
7  
8  
9  
10 20. Sokolova, E., Proshkina, G., Kutova, O., Shilova, O., Ryabova, A., Schulga, A.,  
11 Stremovskiy, O., Zdobnova, T., Balalaeva, I., and Deyev S. (2016) Recombinant Targeted  
12 Toxin Based on HER2-Specific Darpin Possesses a Strong Selective Cytotoxic Effect *in vitro*  
13 and a Potent Antitumor Activity *in vivo*. *J. Control. Release* 233, 48–56.  
14  
15  
16  
17  
18 21. Gebauer, S., Malissek, M., Simon, S., Knauer, S. K., Maskos, M., Stauber, R. H., Peukert,  
19 W., and Treuel, L. (2012) Impact of the Nanoparticle–Protein Corona on Colloidal Stability  
20 and Protein Structure. *Langmuir* 28, 9673–9679.  
21  
22  
23  
24  
25 22. del Pino, P., Pelaz, B., Zhang, Q., Maffre, P., Nienhaus, G. U., and Parak W. J. (2014)  
26 Protein Corona Formation Around Nanoparticles – from the Past to the Future. *Mater. Horiz.*  
27 *1*, 301–313.  
28  
29  
30  
31 23. Lynch, I., and Dawson, K. A. (2008) Protein-Nanoparticle Interactions. *Nano Today* 3,  
32 40–47.  
33  
34  
35  
36 24. Zikich, D., Borovok, N., Molotsky, T., and Kotlyar, A. (2010) Synthesis and AFM  
37 Characterization of Poly(dG)-Poly(dC)-Gold Nanoparticle Conjugates. *Bioconjugate Chem.*  
38 *21*, 544–547.  
39  
40  
41  
42 25. Jana, N. R., Gearheart, L., and Murphy, C. J. (2001) Seeding Growth for Size Control of  
43 5–40 nm Diameter Gold Nanoparticles. *Langmuir* 17, 6782–6786.  
44  
45  
46  
47 26. Liu, X., Atwater, M., Wang, J., and Huo, Q. (2007) Extinction Coefficient of Gold  
48 Nanoparticles with Different Sizes and Different Capping Ligands. *Colloids and Surfaces B:*  
49 *Biointerfaces* 58, 3–7.  
50  
51  
52  
53 27. Mironova, K. E., Chernykh, O. N., Ryabova, A. V., Stremovskiy, O. A., Proshkina, G.  
54 M., and Deyev, S. M. (2014) Highly Specific Hybrid Protein Darpin-Mcherry for Fluorescent  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Visualization of Cells Overexpressing Tumor Marker HER2/neu. *Biochemistry (Mosc.)* 79,  
4  
5 1391–1396.  
6  
7 28. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H.,  
8  
9 Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. *Nucleic Acids Res.* 28,  
10  
11 235-242.  
12  
13 29. Tavanti F., Pedone, A., and Menziani, M. C. (2015) A Closer Look into the Ubiquitin  
14  
15 Corona on Gold Nanoparticles by Computational Studies. *New J. Chem.* 39, 2474–2482.  
16  
17 30. Tavanti, F., Pedone, A., and Menziani, M. C. (2015) Competitive Binding of Proteins to  
18  
19 Gold Nanoparticles Disclosed by Molecular Dynamics Simulations. *J. Phys. Chem. C* 119,  
20  
21 22172–22180.  
22  
23 31. Brancolini, G., Kokh, D. B., Calzolari, L., Wade, R. C., and Corni, S. (2012) Docking of  
24  
25 Ubiquitin to Gold Nanoparticles. *ACS Nano* 6, 9863–9878.  
26  
27 32. Hills, R. D., and Brooks, C. L. (2009) Insights from Coarse-Grained Gō Models for  
28  
29 Protein Folding and Dynamics. *Int. J. Mol. Sci.*, 10, 889–905.  
30  
31 33. Pincus, D. L, Cho, S. S, Hyeon, C, and Thirumalai, D. (2008) Minimal Models for  
32  
33 Proteins and RNA from Folding to Function. *Prog. Mol. Biol. Transl. Sci.* 84, 203-250.  
34  
35 34. Smith, W., and Forester, T. R., J. (1996) DL\_POLY\_2.0: a General-Purpose Parallel  
36  
37 Molecular Dynamics Simulation Package. *Mol. Graph.* 7855, 136–141.  
38  
39 35. Horcas, I., Fernez, R., Gomez-Rodriguez, J. M., Colchero, J., Gomez-Herrero, J., and  
40  
41 Baro, A. M. (2007) WSXM: a Software for Scanning Probe Microscopy and a Tool for  
42  
43 Nanotechnology. *Rev. Sci. Instrum.* 78, 013705.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

TOC

# Synthesis, Characterization and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells

Sergey Deyev, Galina Proshkina, Anastasiya Ryabova, Francesco Tavanti, Maria Cristina Menziani, Gennady Eidelshtein, Gabriel Avishai, Alexander Kotlyar

